Another Zolgensma red flag, another delay in data reporting at Novartis’ AveXis

31st October 2019 Uncategorised 0

Turns out, Novartis’ AveXis unit delayed another report about Zolgensma and its animal-testing data. AveXis has known since March about the safety signal that prompted the FDA to halt enrollment in a trial of Zolgensma as a spinal injection—but left it out of a trial investigator update “by mistake.”

More: Another Zolgensma red flag, another delay in data reporting at Novartis’ AveXis
Source: fierce